Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$116.62M-0.1%$109.82M-3.7%$115.93M+8.8%$118.36M+21.1%$116.75M+33.3%
$33.29M+11.4%$33.19M+15.1%$32.09M+13.9%$31.31M+14.5%$29.87M+12.8%
$149.91M+2.2%$143M+0.1%$148.02M+9.8%$149.67M+19.6%$146.62M+28.5%
-$149.91M-2.2%-$143M-0.1%-$148.02M-9.8%-$149.67M-19.6%-$146.62M-28.5%
$14.69M+6.7%$13.54M-10.0%$12.75M-14.3%$12.42M-13.4%$13.77M+11.7%
-$135.21M-1.8%-$129.47M-1.3%-$135.27M-12.8%-$137.25M-23.9%-$132.86M-30.6%
-$1.41+24.6%-$1.49+18.1%-$1.73+4.4%-$1.89-7.4%-$1.87-3.3%
-$148.72M-2.2%-$141.78M0.0%-$146.82M-9.8%-$148.48M-19.7%-$145.48M-28.7%
-$149.91M-2.2%-$143M-0.1%-$148.02M-9.8%-$149.67M-19.6%-$146.62M-28.5%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is Oric Pharmaceuticals, Inc. profitable?
Oric Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $135.2M over the trailing twelve months.
What is Oric Pharmaceuticals, Inc.'s earnings per share?
Oric Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-1.41.
Where does Oric Pharmaceuticals, Inc.'s income statement data come from?
Every line is extracted from Oric Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.